Chemical Nameedaravone
Dosage FormInjection (intravenous; 30 mg/100 mL)
Drug ClassMiscellaneous
CompanyMitsubishi Tanabe
Approval Year2017


  • To treat patients with amyotrophic lateral sclerosis (ALS).
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Radicava (edaravone) Prescribing Information2018Mitsubishi Tanabe Pharma America, Inc., a US subsidiary of Mitsubishi Tanabe Pharma Corporation, Jersey City, NJ
Document TitleYearSource
Clinical review report: Edaravone (Radicava).2019CADTH